Drug delivery to inflammation based on nanoparticles surface decorated with biomolecules

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3203-3211

  Clares, B ^a   Ruiz, M A ^a   Gallardo, V ^a   Arias, J L ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Arthritis; Enhanced permeation and retention effect; Inflammation; Ligand mediated drug gene delivery; Nanoparticle; Passive drug targeting

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; DEXAMETHASONE; DICLOFENAC; GOLD NANOPARTICLE; IBUPROFEN; INORGANIC COMPOUND; LIPID; LIPOSOME; LUTETIUM 177; METHYLPREDNISOLONE; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; PALMITIC ACID; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMER; POLYSORBATE 80; PREDNISOLONE; RADIOISOTOPE; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRIACYLGLYCEROL; TRIPALMITIN; TRISTEARIN; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; BIOCOMPATIBILITY; BIODEGRADATION; CHEMICAL MODIFICATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; EMULSION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VIVO STUDY; INFLAMMATION; LIPID BILAYER; LIPOGENESIS; LIPOSOMAL DELIVERY; MICROEMULSION; MOLECULE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; RABBIT; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; NANOPARTICLES;

EID: 84863682372     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784676     Document Type: Review

References (144)

1. Brown, P.H.; Blundell, G.; Greening, A.P.; Crompton, G.K. Screening for hypothalamic-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir. Med., 1999, 185, 511-516.
2. O'Byrne, P.M.; Pedersen, S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J. Allergy Clin. Immunol., 1998, 102, 879-886.
3. Pedersen, S.; O'Byrne, P.M. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy, 1997, 52, 1-34.
4. Jain, P.; Mishra, A.; Yadav, S.K.; Patil, U.K.; Baghel, U.S. Formulation development and characterization of solid lipid nanoparticles containing nimesulide. Int. J. Drug. Deliver. Technol., 2009, 1, 24-27.
5. Freitas, M.N.; Marchetti, J.M. Nimesulide PLA microspheres as a potential sustained release system for the treatment of inflammatory diseases. Int. J. Pharm., 2005, 295, 201-211.
6. Bernardi, A.; Zilberstein, A.C.C.V.; Jager, E.; Campos, M.M.; Morrone, F.B.; Calixto, J.B.; Pohlmann, A.R.; Gutierres, S.S.; Battastini, A.M.O. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. B r. J. Pharmacol., 2009, 158, 1104-1111.
7. Ishihara, T.; Kubota, T.; Choi, T.; Higaki, M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther., 2009, 329, 412-417.
8. Lu, X.; Howard, M.D.; Mazik, M.; Talbert, D.R.; Rinehart, J.J.; Potter, P.M.; Jay, M.; Leggas, M. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J., 2009, 11, 120-122.
9. Chellat, F.; Merhi, Y.; Moreau, A.; Yahia, L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 2005, 26, 7260-7275.
10. Barrera, P.; Bloom, A.; van Lent, P.L.; van Bloois, L.; Beijnen, J.H.; van Rooijen, N.; de Waal Malefijit, M.C.; van de Putte, L.B.; Storm, G.; van den Berg, W.B. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheumat., 2000, 43, 1951-1959.
11. Ruiz, M.A.; Clares, B.; Morales, M.E.; Gallardo, V. Vesicular lipidic systems, liposomes, PLO, and liposomes-PLO: characterization by electronic transmission microscopy. Drug Dev. Ind. Pharm., 2008, 34, 1269-1276.
12. Shoji, Y.; Mizushima, Y.; Yanagawa, A.; Shiba, T.; Takei, H.; Fuji, M.; Amino, M. Enhancement of antiinflammatory effects of biphenyl acetic acid by its incorporation into lipid microspheres. J. Pharm. Pharmacol., 1986, 38, 118-121.
13. Arias, J.L. Drug targeting strategies in cancer treatment: an overview. Mini Rev. Med. Chem., 2011, 11, 1-17.
14. Arias, J.L. Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging. Expert Opin. Drug. Deliv., 2011, 8, 1589-1608.
15. Dingle, J.T.; Gordon, J.L.; Hazleman, B.L.; Knight, C.G.; Thomas D.P.; Philips, N.C.; Shaw, I.H.; Fildes, F.J.T.; Oliver, J.E.; Jones, G.; Turner, E.H.; Lowe, J.S. Novel treatment for joint inflammation. Nature, 1978, 271, 372-373.
16. Kaur, K.; Jain, S.; Sapra, B.; Tiwary, AK. Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation. Curr. Drug Deliv., 2007, 4, 276-282.
17. Türker, S.; Erdoǧan, S.; Özer, A.Y.; Ergün, E.L.; Tuncel, M.; Bilgili, H.; Deveci, S. Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. Int. J. Pharm., 2005, 296, 34-43.
18. Herbst, S.M.; Klegerman, M.E.; Kim, H.; Qi, J.; Shelat, H.; Wassler, M. Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1. Mol. Pharm., 2009, 7, 3-11.
19. Serpe, L.; Canaparo, R.; Daperno, M.; Sostegni, R.; Martinasso, G.; Muntoni, E.; Ippolito, L.; Vivenza, N.; Pera, A.; Eandi, M.; Gasco, M.R.; Zara, G.P. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur. J. Pharm. Sci., 2010, 39, 428-436.
20. Horning, S.; Bunjes, H.; Heinze, T. Preparation and characterization of nanoparticles based on dextran-drug conjugates. J. Colloid Interface Sci., 2009, 338, 56-62.
21. Feng, M.; Li, P. Amine-containing core-shell nanoparticles as potential drug carriers for intracellular delivery. J. Biomed. Mater. Res. A, 2007, 80, 184-193.
22. Kim, W.U.; Lee, W.K.; Ryoo, J.W.; Kim, S.H.; Kim, J.; Youn, J.; Min, S.Y.; Bae, E.Y.; Hwang, S.Y.; Park, S.H.; Cho, C.S.; Park, J.S.; Kim, H.Y. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum., 2002, 46, 1109-1120.
23. Yasukawa, T.; Ogura, Y.; Tabata, Y.; Kimura, H.; Wiedemann, P.; Honda, Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res., 2004, 23, 253-281.
24. Diebold, Y.; Calonge, M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res., 2010, 29, 596-609.
25. Thunus, L.; Dauphin, J.F.; Moiny, G.; Deby, C.; Deby-Dupont, G. Anti-inflammatory properties of copper, gold and silver, individually and a mixtures. Analyst, 1995, 120, 967-973.
26. Wong, K.K; Cheung, S.O; Huang, L.; Niu, J.; Tao, C.; Ho, C.M.; Che, C.M.; Tam, P.K. Further evidence of the anti-inflammatory effects of silver nanoparticles. ChemMedChem, 2009, 4, 1129-1135.
27. Giljohann, D.A.; Seferos, D.S.; Patel, P.C.; Millstone, J.E.; Rosi, N.L.; Mirkin, C.A. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett., 2007, 7, 3818-3821.
28. Ghosh, P.; Han, G.; De, M.; Kim, C.K.; Rotillo, V.M. Gold nanoparticles in delivery applications. Adv. Drug. Deliv. Rev., 2008, 60, 1307-1315.
29. Lee, H.; Lee, K., Kim, I.K.; Park, T.G. Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes. Biomaterials, 2008, 29, 4709-4718.
30. Tian, J.; Wong, K.K.; Ho, C.M.; Lok, C.N.; Yu, W.Y.; Che, C.M.; Chiu, J.F.; Tam, P.K. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem., 2007, 2, 129-136.
31. Yang, Y.J.; Tao, X.; Hou, Q.; Chen, J.F. Fluorescent mesoporous silica nanotubes incorporating CdS quantum dots for controlled release of ibuprofen. Acta Biomater., 2009, 5, 3488-3496.
32. Slowing, I.I.; Vivero-Escoto, J.L.; Wu, C.; Lin, V.S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev., 2008, 60, 1278-1288.
33. Wen, L.X.; Ding, H.M.; Wang, J.X.; Chen, J.F. Porous hollow silica nanoparticles as carriers for controlled delivery of ibuprofen to small intestine. J. Nanosci. Nanotechnol., 2006, 6, 3139-3144.
34. Tsagkogeorgas, F.; Ochsenkühn-Petropoulou, M.; Niessner, R.; Knopp, D. Encapsulation of biomolecules for bioanalytical purposes: preparation of diclofenac antibody-doped nanometer-sized silica particles by reverse micelle and sol-gel processing. Anal. Chim. Acta., 2006, 28, 133-137.
35. Butoescu, N.; Jordan, O.; Burdet, P.; Hebert, C.; Stadelmann, P.; Petri-Fink, A.; Hofmann, H.; Doelker, E. Dexamethasone-containing biodegradable superparamagnetic microparticles for intra-articular administration: physicochemical and magnetic properties, and in vitro and in vivo drug release. Eur. J. Pharm. Biopharm., 2009, 72, 529-538.
36. Butoescu, N.; Jordan, O.; Petri-Fink, A.; Hofmann, H.; Doelker, E. Coencapsulation of dexamethasone 21-acetate and SPIONs into biodegradable polymeric microparticles designed for intra-articular delivery. J. Micoencapsul., 2008, 25, 339-350.
37. Butoescu, N.; Seemayer, C.A.; Palmer, G.; Guerne, P.A.; Gabay, C.; Doelker, E.; Jordan, O. Magnetically retainable microparticles for drug delivery to the joint: efficacy studies on an antigen-induced arthritis model in mice. Arthritis Res. Ther., 2009, 11, R72.
38. Sun, H.W.; Zhang, L.Y.; Zhu, X.J.; Warig, X.F. Magnetic poly(PEGMA-MAA) nanoparticles: photochemical preparation and potential application in drug delivery. J. Biomater. Sci. Polvm. Ed., 2009, 20, 1675-1686.
39. Kim, G.C.; Li, Y.Y.; Chu, Y.F.; Cheng, S.X.; Zhang, X.Z.; Zhuo, R.X. A nanosized, thermo-sensitive drug carrier: self-assembled Fe(3)O(4)-OA-g-P(OA-co- NIPAAm) magnetomicelles. J. Biomater. Sci. Polym. Ed., 2008, 19, 1249-1259.
40. Leserman, L.D.; Weinstein, J.N.; Blumenthal, R.; Terry, W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. USA, 1980, 77, 4089-4093.
41. Wu, P.; Tin, G.W.; Baldeschwieler, J.D. Phagocytosis of carbohydrate-modified phospholipid vesicles by macrophages. Proc. Natl. Acad. Sci. USA, 1981, 78, 2033-2037.
42. Singhal, A.; Bali, A.; Jain, R.K.; Gupta, C.M. Specific interactions of liposomes with PMN leucocytes upon incorporating tuftsin in their bilayers. FEBS Lett., 1984, 178, 109-113.
43. Arias, J.L.; Clares, B.; Morales, M.E.; Gallardo, V; Ruiz, M.A. Lipid-based drug delivery systems for cancer treatment. Curr. Drug Targets, 2011, 12, 1151-1165.
44. Brouwers, A.H.; De Jong, D.J.; Dams, E.T.; Oyen, W.J.; Boerman, O.C.; Laverman, P.; Naber, T.H.; Storm, G.; Corstens, F.H. Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease. J. Drug Target., 2000, 8, 225-233.
45. Linker, R.A.; Weller, C.; Lühder, F.; Mohr, A.; Schmidt, J.; Knauth, M.; Metselaar, J.M.; Gold, R. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol., 2008, 211, 397-406.
46. Metselaar, J.M.; Wauben, M.H.M.; Wagenaar-Hilbers, J.P.A.; Boerman, O.C.; Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum., 2003, 48, 2059-2066.
47. Schmidt, J.; Metselaar, J.M.; Wauben, M.H.M.; Toyka, K.V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.
48. Lopez-Garcia, F.; Vazquez-Auton, J.M.; Gil, F.; Latoore, R; Moreno, F.; Villalain, J.; Gomez-Fernandez, J.C. Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. J. Pharm. Pharmacol., 1993, 45, 576-578.
49. Axelsson, B. Liposomes as carriers for anti-inflammatory agents. Adv. Drug Deliv. Rev., 1989, 3, 391-404.
50. Elron-Gross, I.; Glucksam, Y.; Margalit, R. Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment. Int. J. Pharm., 2009, 376, 84-91.
51. Jukanti, R.; Devaraj, G.; Devaraj, R.; Apte, S. Drug targeting to inflammation: studies on antioxidant surface loaded diclofenac liposomes. Int. J. Pharm., 2011, 414, 179-185.
52. Bard, D.R.; Knight, C.G.; Page Thomas, D.P. The retention and distribution in the rabbit knee of a radionuclide complexed with a lipophilic chelator in liposomes. Clin. Exp. Rheumatol., 1983, 1, 113-117.
53. Bard, D.R.; Knight, C.G.; Page Thomas, D.P. Effect of intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Clin. Exp. Rheumatol., 1985, 3, 237-242.
54. Dharma, S.K.; Fishman, P.H.; Peyman, G.A. A preliminary study of corneal penetration of 125I-labelled iodoxuridine liposome. Acta Ophthalmol. (Copenh.), 1986, 64, 298-301.
55. Schaeffer, H.E.; Brietfelter, J.M.; Krohn, D.L. Lectin mediated attachment of liposomes to cornea: influence on transcorneal drug flux. Invest. Ophthalmol. Vis. Sci., 1982, 23, 530-533.
56. Mezei, M.; Gulasekharam, V. Liposomes a selective drug delivery system for the topical route of administration I: lotion dosage form. Life Sci., 1980, 26, 1473-1477.
57. Mezei, M.; Gulasekharam, V. Liposomes a selective drug delivery system for the topical route of administration: gel dosage form. J. Pharm. Pharmacol., 1982, 34, 473-474.
58. Carafa, M.; Santucci, E.; Alhaique, F.; Coviello, T., Murtas, E., Riccieri, F.M.; Lucania, G.; Torrisi, M.R. Preparation and properties of new unilamellar non-ionic surfactant vesicles. Int. J. Pharm., 1998, 160, 51-59.
59. Parhi, R.; Suresh, P. Preparation and characterization of solid lipid nanoparticles-a review. Curr. Drug Discov. Technol., 2012, 9, 2-16.
60. Wissing, S.A.; Kayser, O.; Muller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56, 1257-1272.
61. Santos, M.C.; Mehnert, W.; Schafer-Korting, M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm., 2000, 196, 165-167.
62. Santos M.C.; Mehnert, W.; Schaller, M.; Korting, H.C.; Gysler, A.; Haberland, A.; Schäfer-Korting, M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug. Target., 2002, 10, 489-495.
63. Xiang, Q.Y.; Wang, M.T.; Chen, F.; Gong, T.; Jian, Y.L.; Zhang, Z.R.; Huang, Y. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch. Pharm. Res., 2007, 30, 519-525.
64. zur Mühlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 1998, 45, 149-155.
65. Thakkar, H.; Kumar Sharma, R.; Murthy, RS. Drugs R.D. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs, 2007, 8, 275-285.
66. Potta SG, Minemi S, Nukala RK, Peinado C, Lamprou DA, Urquhart A, Douroumis D. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility. J. Microencapsul., 2011, 28, 74-81.
67. Abdel-Mottaleb, M.M.; Neumann, D.; Lamprecht, A. In vitro drug release mechanism from lipid nanocapsules (LNC). Int. J. Pharm., 2010, 390, 208-213.
68. Paolicelli, P.; Cerreto, F.; Cesa, S.; Feeney, M.; Corrente, F.; Marianecci, C.; Casadei, MA. Influence of the formulation components on the properties of the system SLN-dextran hydrogel for the modified release of drugs. J. Microencapsul., 2009, 26, 355-364.
69. Rothenfluh, D.A.; Bermudez, H.; O'Neil, C.P.; Hubbell, J.A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat. Mater., 2008, 7, 248-254.
70. Adibkia, K.; Siahi Shadbad, M.R.; Nokhodchi, A.; Javadzedeh, A. Barzegar-Jalali, M.; Barar, J.; Mohammadi, G.; Omidi, Y. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J. Drug Target., 2007, 15, 407-416.
71. Adibkia, K; Omidi, Y.; Siahi, M.R.; Javadzadeh, A.R.; Barzegar-Jalali, M.; Barar, J.; Maleki, N.; Mohammadi, G.; Nokhodchi, A. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J. Ocular Pharmacol. Ther., 2007, 23, 421-432.
72. Kassem, M.A.; Abdel Rahman, A.A.; Ghorab, M.M.; Ahmed, M.B.; Khalil, R.M. Nanosuspensions as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm., 2007, 340, 126-133.
73. Sasaki, H.; Yamamura, K.; Mukai, T.; Nishida, K.; Nakamura, J.; Nakashima, M.; Ichikawam, M. Enhancement of ocular drug penetration. Crit. Rev. Ther. Drug Carrier Syst., 1999, 16, 85-146.
74. Radwan, M.A.; AlQuadeib, B.T.; Aloudah, N.M.; Aboul Enein, H.Y. Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats. Int. J. Pharm., 2010, 397, 173-178.
75. Liu, M.; Dong, J.; Yang, Y.; Yang, X.; Xu, H.J. Anti-inflammatory effects of triptolide loaded poly(D, L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. J. Ethnopharmacol., 2005, 97, 219-25.
76. Bucolo, C.; Maltese, A.; Puglisi, G.; Pignatello, R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by a Eudragit RS100® nanoparticle suspension. Ophthalmic Res., 2002, 34, 319-323.
77. Pignatello, R.; Bucolo, C.; Ferrara, P.; Maltese, A.; Puleo, A.; Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci., 2002, 16, 53-61.
78. Thakkar, H.; Sharma, RK.; Mishra, AK.; Chuttani, K.;Murthy, R.S.R. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. J. Pharm. Pharmacol., 2004, 56, 1091-1099.
79. Zhang, X.; Yu, C.; Xushi; Zhang, C.; Tang, T.; Dai, K. Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. Biochem. Biophys. Res. Commun., 2006, 341, 202-208.
80. Fernandes, J.C.; Wang, H.; Jreyssaty, V.; Benderdour, M.; Lavigne, P.; Qiu, X.; Winnik, F.M.; Zhang, X.; Dai, K.; Shi, Q. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther., 2008, 16, 1243-1251.
81. Higaki, M.; Ishihara, T.; Izumo, N; Takatsu, M.; Mizushima, Y. Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis., 2005, 64, 1132-1136.
82. Vega E, Gamisans F, García ML, Chauvet A, Lacoulonche F, Egea MA. PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J. Pharm. Sci, 2008, 97, 5306-5317.
83. Horisawa, E.; Hirota, T.; Kawazoe, S.; Yamada, J.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Prolonged anti-inflammatory action of dl-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antig en-induced arthritic rabbit. Pharm. Res., 2000, 19, 403-410.
84. Kim, J.T.; Caldwell, J.M.; Bellamkonda, R.V. Nanoparticle-mediated local delivery of methylprednisolone after spinal cord injury. Biomaterials, 2009, 30, 2582-2590.
85. Arias, J.L.; López-Viota, M.; Sáez-Fernández, E.; Ruiz, M.A. Formulation and physic o chemical characterization of poly(epsilon-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium. Colloids Surf. B Biointerfaces, 2010, 75, 204-208.
86. Jain, S.K.; Chourasia, M.K.; Masuriha, R.; Soni, V.; Jain, A.; Jain, N.K.; Gupta, Y Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv., 2005, 12, 207-215.
87. Calvo, P.; Alonso, M.J.; Vila-Jato, J.L.; Robinson, J.R. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol, 1996, 48, 1147-1152.
88. Gürsoy, A.; Ero. lu, L.; Ulutin, Ç.; Taşyürek, M.; Fessi, H.; Puisieux, F.; Devissaguet, J.P Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation. Int. J. Pharm., 1989, 52, 101-108.
89. Vega, E.; Egea, M.A.; Valls, O.; Espina, M.; García, M.L. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J. Pharm. Sci, 2006, 95, 2393-2405.
90. Khan M, Wiradharma N, Beniah G, Bte N, Rafiq M, Liu S, Au J, Yang Y Y. Branched disulfide-based polyamidoamines capable of mediating high gene transfection. Curr Pharm Des., 2010, 16, 2341-2349.
91. Turnbull, W.B.; Stoddart, J.F. Design and synthesis of glycodendrimers. J. Biotechnol, 2002, 90, 231-255.
92. Li, Y; Tseng, YD.; Kwon, S.Y; D'Espaux, L.; Bunch, J.S.; McEuen, PL. Controlled assembly of dendrimer-like DNA. Nat. Mater, 2004, 3, 38-42.
93. Prajapati, R.N.; Tekade, R.K.; Gupta, U.; Gajbhiye, V; Jain, N.K. Dendrimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm., 2009, 6, 940-950.
94. Perumal, O.; Khandare, J.; Kolhe, P; Kannan, S.; Lieh-Lai, M.; Kannan, RM. Effects of branching architecture and linker on the activity of hyperbranched polymer-drug conjugates. Bioconjug. Chem., 2009, 20, 842-846.
95. Chauhan, A.S.; Sridevi, S.; Chalasani, K.B.; Jain, A.K.; Jain, S.K.; Jain, N.K.; Diwana, P.V. Dendrimer mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release, 2003, 90, 335-343.
96. Kurtoglu, Y.E.; Mishra, M.K.; Kankan, S.; Kankan, R.M. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int. J. Pharm., 2010, 384, 189-194.
97. Torchilin, V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci, 2004, 61, 2549-2559.
98. Wang, L.; Zeng, R.; Li, C; Qiao, R. S elf-assembled p o ly pep tide-b lock-poly (vinylpyrr o lidone) as prospective drug-delivery systems. Colloids Surf B Biointerfaces, 2009, 74, 284-292.
99. Zhang, J.X.; Li, X.J.; Qiu, L.Y; Li, X.H.; Yan, M.Q.; Jin, Y; Zhu, K.J. Indomethacin-loaded polymeric nanocarriers based on amphiphilic polyphosphazenes with poly (N-isopropylacrylamide) and ethyl tryptophan as side groups: Preparation, in vitro and in vivo evaluation. J. Control. Release, 2006, 116, 322-329.
100. Lin, S.Y; Kawashima, Y The influence of three poly(oxyethylene) poly(oxypropylene) surface-active block copolymers on the solubility behavior of indomethacin. Pharm. Acta Helv, 1985, 60, 339-344.
101. Wei, H.; Zhang, X.; Cheng, C; Cheng, S.X.; Zhuo, R.X. Self-assembled, thermosensitive micelles of a star block copolymer based on PMMA and PNIPAAm for controlled drug delivery. Biomaterials, 2007, 28, 99-107.
102. Wei, H.; Zhang, X.Z.; Chen, W.Q.; Cheng, S.X.; Zhuo, R.X. S elf-assembled thermo sensitive micelles based on poly(L-lactide-star block-N- isopropylacrylamide) for drug delivery. J. Biomed. Mater. Res. A, 2007, 83, 980-989.
103. Gupta, A.K.; Madan, S.; Majumdar, D.K.; Maitra, A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular antiinflammatory studies. Int. J. Pharm., 2000, 209, 1-14.
104. Abu Lila, A.S.; Doi, Y; Nakamura, K.; Ishida, T.; Kiwada, H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J. Control. Release, 2010, 142, 167-173.
105. Zara, G.P; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10, 327-335.
106. Bisht, S.; Maitra, A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1, 415-425.
107. Mitra, S.; Gaur, U.; Ghosh, P.C.; Maitra, A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release, 2001, 74, 317-323.
108. Son, Y.J.; Jang, J.S.; Cho, Y.W.; Chung, H.; Park, R.W.; Kwon, I.C.; Kim, I.S.; Park, J.Y.; Seo, S.B.; Park, C.R.; Jeong, S.Y. Biodistribution and antitumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release, 2003, 91, 135-145.
109. Hau, P.; Fabel, K.; Baumgart, U.; Rummele, P.; Grauer, O.; Bock, A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hübner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 2004, 100, 1199-1207.
110. Shenoy, D.B.; Amiji, M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 2005, 293, 261-270.
111. Ye, J.; Wang, Q.; Zhou, X.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm., 2008, 352, 273-279.
112. Ulbrich, W.; Lamprecht, A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface, 2010, 7, S55-S66.
113. Allen, T.M.; Murray, L.; MacKeigan, S.; Shah, M. Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution. J. Pharmacol. Exp. Ther., 1984, 229, 267-275.
114. Kamps, J.A.; Scherphof, G.L. Biodistribution and uptake of liposomes in vivo. Methods Enzymol., 2004, 387, 257-266.
115. Poste, G.; Bucana, C.; Ray, A.; Bugelski, P.; Kirsch, R.; Fidler, I.J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res., 1982, 42, 1412-1422.
116. Ahsana, F.; Rivas, I.P.; Mansoor, A.K.; Torres A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers liposomes and microspheres on the phagocytosis by macrophages. J. Control. Release, 2002, 79, 29-40.
117. van Rooijen, N.; van Kesteren-Hendrikx, E. Clodronate liposomes: perspectives in research and therapeutics. J. Liposome Res., 2002, 12, 81-94.
118. Lo, C.T.; Van Tassel, P.R.; Saltzman, W.M. Poly(lactide-co-glycolide) nanoparticle assembly for highly efficient delivery of potent therapeutic agents from medical devices. Biomaterials, 2010, 1, 3631-3642.
119. Paleolog, E.M.; Fava, R.A. Angiogenesis in rheumathoid arthritis: implications for future therapeutic strategies. Springer Semin. Immunopathol., 1998, 20, 73-94.
120. Essa, S.; Rabanel, J.M.; Hildgen, P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles. Eur. J. Pharm. Biopharm., 2010, 75, 96-106.
121. Essa, S.; Rabanel J.M; Hildgen, P. Effect of aqueous solubility of grafted moiety on the physicochemical properties of poly(d, l-lactide) (PLA) based nanoparticles. Int. J. Pharm., 2010, 388, 263-273.
122. Sandanaraj, B.S.; Gremlich, H.U.; Kneuer, R.; Dawson, J.; Wacha. S. Fluorescent nanoprobes as a biomarker for increased vascular permeability: implications in diagnosis and treatment of cancer and inflammation. Bioconjug. Chem., 2010, 21, 93-101.
123. Konduri, K.S.; Nandedkar, S.D.; Duzgunes, N.; Suzara, V.; Artwohl, J.; Bunte, R.; Gangadharam, P.R.J. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol., 2003, 111, 321-327.
124. Schroeder, A.; Sigal, A.; Turjeman, K.; Barenholz, Y. Using PEGylated nano-liposomes to target tissue invaded by a foreign body. J. Drug Target., 2008, 16, 591-595.
125. Konduri, K.S.; Nandedkar, S.D.; Düzgünes, N.; Suzara, V.; Artwohl, J.; Bunte, R.; Gangadharam, P.R.J. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol., 2003, 111, 321-327.
126. Ishihara, T.; Takahashi, M.; Higaki, M.; Mizushima, Y.; Mizushima T. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int. J. Pharm., 2010, 385, 170-175.
127. Srinath, P.; Vyas, S.P.; Diwan, P. V. Effect of lipid composition of biodisposition of liposomes of indomethacin in arthritic rats. Pharmacy and Pharmacol. Comm., 1999, 5, 1-7.
128. Jubeli, E.; Moine, L.; Nicolas, V.; Barratt, G. Preparation of E-selectin-targeting nanoparticles and preliminary in vitro evaluation. Int. J. Pharm., 2012, 426, 291-301.
129. Aramaki, Y.; Murai, M.; Tsuchiya, S. Activation of Fc receptor mediated phagocytosis by mouse peritoneal macro phages following the intraperitoneal administration of liposomes. Pharm. Res., 1994, 11, 518-521.
130. Dutta, M.; Bandyopadhyay, R.; Basu, M.K. Neoglycosylated liposomes as efficient ligand for the evaluation of specific sugar receptors on macrophages in health and in experimental leishmaniasis. Parasitology, 1994, 109, 139-147.
131. Homem de Bittencourt, P.I.Jr.; Lagranha, D.J.; Maslinkiewicz, A.; Senna, S.M; Tavares, A.M.; Baldissera, L.P. LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis, 2007, 193, 245-258.
132. Lestini, B.J.; Sagnella, S.M.; Xu, Z.; Shive, M.S.; Richter, N.J.; Jayaseharan, J.; Case, A.J. Kottke-Marchantc, K.; Andersonb, J.M.; Marchanta. R.E. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control. Release, 2002, 78, 235-247.
133. Garrood, T.; Pitzalis, C. Targeting the inflamed synovium: the quest for Selectivity. Arthritis Rheum., 2006, 54, 1055-1060.
134. Rothenfluh, D.A.; Bermudez, H.; O'Neil, C.P.; Hubbell, J.A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage, Nat. Mater., 2008, 7, 248-254.
135. Howard, K.A.; Paludan, S.R.; Behlke, M.A.; Besenbacher, F.; Deleuran, B.; Kjems, J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther., 2009, 17, 162-168.
136. Zhou, H.F.; Chan, H.W.; Wickline, S.A.; Lanza, G.M.; Pham, C.T. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J., 2009, 23, 2978-2985.
137. Koning, G.A.; Schiffelers, R.M.; Wauben, M.H.; Kok, R.J.; Mastrobattista, E.; Molema, G.; ten Hagen, T.L.M.; Storm, G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum., 2006, 54, 1198-1208.
138. Asgeirsdottir; S.A.; Zwiers, P.J; Morselt, H.W.; Moorlag, H.E.; Bakker, H.I.; Heeringa, P. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Ren. Physiol., 2008, 294, F554-F561.
139. Hashida, N.; Ohguro, N.; Yamazaki, N.; Arakawa, Y.; Oiki, E.; Mashimo, H. High efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp. Eye Res., 2008, 86, 138-149.
140. Rudd, J.H.F.; Warburton, E.A.; Fryer, T.D.; Jones, H.A.; Clark, J.C.; Antoun, N.; Johnstrom, P.; Davenport, A.P.; Kirkpatrick, P.J.; Arch, B.N.; Pickard, J.D.; Weissberg, P.L. Imaging atherosclerotic plaque inflammation with [F-18]-fluorodeoxyglucose positron emission tomography. Circulation, 2002, 105, 2708-2711.
141. Kim, J.S.; An, H.; Rieter, W.J.; Esserman, D.; Taylor-Pashow, K.M.; Sartor, R.B.; Lin, W.; Lin, W.; Tarrant, T.K. Multimodal optical and Gd-based nanoparticles for imaging in inflammatory arthritis. Clin. Exp. Rheumatol., 2009, 27, 580-586.
142. McAteer, M.A.; Sibson, N.R.; von Zur Muhlen, C.; Schneider, J.E.; Lowe, A.S.; Warrick, N. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat. Med., 2007, 13, 1253-1258.
143. 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med., 2008, 49, 103-111.
144. Tsourkas, A.; Shinde-Patil, V.R.; Kelly, K.A.; Patel, P.; Wolley, A.; Allport, J.R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug. Chem., 2005, 16, 576-581.